Journal article
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non–Small Cell Lung Cancer in China
Abstract
PURPOSE: To assess the cost-effectiveness of osimertinib used as a second-line treatment after failure of epidermal growth factor receptor tyrosine kinase inhibitor therapy for advanced non-small cell lung cancer (NSCLC) in China.
METHODS: From the perspective of China's health care system, a Markov model was used for estimating the costs and health outcomes of osimertinib and 4 platinum-based chemotherapies, including pemetrexed + platinum …
Authors
Guan H; Liu G; Xie F; Sheng Y; Shi L
Journal
Clinical Therapeutics, Vol. 41, No. 11, pp. 2308–2320.e11
Publisher
Elsevier
Publication Date
November 2019
DOI
10.1016/j.clinthera.2019.09.008
ISSN
0149-2918
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AcrylamidesAniline CompoundsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChinaCisplatinCost-Benefit AnalysisDeoxycytidineDocetaxelErbB ReceptorsHumansLung NeoplasmsMiddle AgedMutationPaclitaxelPemetrexedProtein Kinase InhibitorsQuality-Adjusted Life YearsRandomized Controlled Trials as TopicGemcitabine